Triple Negative Breast Cancer (TNBC) is a subtype of breast cancer characterized by the absence of three common receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This subtype is particularly aggressive and constitutes about 10-20% of all breast cancer cases. The absence of these receptors makes TNBC challenging to treat with conventional hormonal and targeted therapies.